SkyBRIGHT Study

A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Patients Treated with SKYTROFA (lonapegsomatropin) (SkybriGHt)

SkyBright

Ages: 1 to 18 years old on treatment of SKYTROFA (Lonapegsomatropin)

  • Patients are managed according to routine clinical care. 
  • Clinical Outcome Assessments (COAs) are collected at minimum of every 6 months, or whenever the patient visits the site as per the standard of care.
  • Patients are followed for at least 5 years or whenever they stop taking SKYTROFA. 
 
Interested? Either call Dr. Miller's Research team at 612-624-0519 or email at [email protected]
 
Also, the study can be found on Clinical Trials.gov at: